Form 4: Natera Executive Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock in pre-planned transactions.
Summary
- Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported the sale of 3,000 shares of Natera common stock.
- The sales occurred on August 1, 2025, and were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
- The shares were sold in three separate transactions at weighted average prices of $132.4528, $133.3097, and $134.08.
- Following these transactions, Mr. Moshkevich beneficially owns 123,059 shares of Natera common stock.
Sentiment
Score: 5
Explanation: The sale of shares by a key executive, while reducing insider ownership, was conducted under a pre-arranged Rule 10b5-1 trading plan. This indicates a scheduled transaction rather than a discretionary sale based on immediate market or company performance, thus having a neutral to slightly negative sentiment.
Negatives
- A key executive, Solomon Moshkevich, sold 3,000 shares of common stock, which reduces insider ownership.
Risks
- Potential for negative market perception due to insider share sales, even if pre-planned.
Future Outlook
NA
Management Comments
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
Industry Context
NA
Stakeholder Impact
- Shareholders: Reduced insider ownership, which could be perceived negatively by some investors, though the 10b5-1 plan mitigates this.
Key Dates
| Date | Description |
|---|---|
| 11/26/2024 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 08/01/2025 | Date of share transactions. |
| 08/05/2025 | Date the Form 4 was signed. |
Recommendation
holdThe reported insider sale was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a scheduled liquidity event rather than a reflection of management's immediate outlook on the company's prospects. This type of transaction typically does not provide a strong signal for a change in investment recommendation.
Keywords
Natera, NTRA, Insider Trading, Form 4, Share Sale, 10b5-1 Plan, Solomon Moshkevich, Clinical Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.